The US Food and Drug Administration (FDA) has approved Australia-based Mayne Pharma Group Limited's (ASX: MYX) SORILUX (calcipotriene) Foam, 0.005% to treat adolescents, it was reported yesterday.
The product is now approved for treating plaque psoriasis of the scalp and body in patients aged 12 years and older. SORILUX Foam contains calcipotriene, a synthetic vitamin D analogue that has a similar receptor binding affinity as natural vitamin D. The exact mechanism of action contributing to the clinical efficacy is unknown.
The FDA first approved the product for treating adults with plaque psoriasis in 2010, based on evidence from two eight-week placebo controlled clinical trials in patients with mild to moderate plaque psoriasis of the body and one eight-week placebo controlled clinical trial in patients with moderate plaque psoriasis of the scalp. Further data was received in a follow-on open label study in patients aged 12 to 17 years of age with psoriasis.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT